Corporate social responsibility

Corporate social responsibility

Our commitment to corporate social responsibility (CSR) is incorporated in our company’s core purpose and our vision, which is to find new ways to improve healthcare and quality of life for patients and their families with our novel mode of action medicines. We believe we have a responsibility to ensure our actions not only benefit our main stakeholders (patients, shareholders and employees), but also society as a whole. At Galapagos, being socially responsible is already a consideration in everything we do.

Our core business is discovery of breakthrough therapies for diseases with large unmet medical need. On a daily basis, we aim to make a lasting contribution to society with our discovery and clinical development efforts. Filgotinib, GLPG1690, and MOR106 have shown the first clinical examples of how our approach to finding novel mechanism of action medicines may be able to make a difference for patients in many disease areas. We have a substantial pipeline of new mechanism of action candidate medicines in inflammation and fibrosis, which we are committed to developing until we ascertain the impact they could have on patients. We aim to bring impactful medicines to patients ourselves.

In our business operations we strive to comply with all relevant laws, standards, and guidelines. We also consider the well-being of our employees a priority, and we aim to minimize our impact on the environment. We have high ethical standards and aim to conduct business with companies and within countries that share our ethics and respect the protection of internationally proclaimed human rights. We aim to support and respect the protection of human rights through policies that address responsible supplier management, ethical procedures, and health and safety procedures.

The table below provides the references to the sections of our annual report in which the non-financial information required by article 96, §4 and article 119, §2 of the Belgian Companies Code is disclosed. We have the ambition to report in the future according to frameworks such as the Global Reporting Initiative (GRI) Sustainability Reporting Standards (SRS) and European Federation of Financial Analysts Societies Guideline for the Integration of ESG into Financial Analysis and Corporate Valuation.

Diversity of our board of directors and executive committee